Recursion Pharmaceuticals (RXRX) Earnings Date & Reports

Key Takeaways

• Recursion reported third-quarter 2026 revenue of $18.6 million, up from $5.2 million a year earlier, driven by a $10 million milestone payment from its Sanofi collaboration.
• Net loss narrowed to $119.0 million from $162.3 million in the prior-year quarter, helped by lower research and development (R&D) and general and administrative (G&A) spending.
• The loss per share of $0.22 came in narrower than the consensus estimate of a $0.24 loss, while revenue exceeded expectations.
• Pro forma cash of roughly $748.7 million, including an October follow-on offering, supports a runway that now extends into 2029.
• Updated clinical data for REC-4881 and REC-1245, plus a new Sanofi option exercise, reinforced the company's pipeline momentum.
• Management reiterated full-year 2026 cash operating expense guidance of less than $375 million and set 2027 guidance below $360 million.
• For more information on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for additional details and context.
• Explore Trending AI Robots to see how AI-driven strategies are tracking momentum and trade ideas across the market.

Earnings Context and Why It Matters

As a clinical-stage, AI-enabled drug discovery company with no approved products yet, Recursion's quarterly reports are watched less for traditional revenue and more for three things: cost discipline, cash runway, and clinical or partnership milestones that validate its platform. This report delivered on all three fronts. The top line was lifted by a lumpy but meaningful collaboration milestone from Sanofi, while tighter spending and a fresh capital raise extended the company's runway further into the future. For investors, the bigger story sits in the updated data for REC-4881 and REC-1245 and the continued willingness of large pharmaceutical partners to option its AI-generated drug candidates, which together shape confidence in Recursion's core promise of turning machine-driven discovery into medicines.

Reported Results

Recursion reported total revenue of $18.6 million for the third quarter of 2026, up from $5.2 million in the same period a year earlier. The increase was driven primarily by a $10.0 million milestone payment from Sanofi, which exercised an option on the first development candidate from the companies' collaboration. Net loss narrowed to $119.0 million from $162.3 million in the prior-year quarter, while the net loss per share of $0.22 came in narrower than the consensus estimate of a $0.24 loss. R&D expenses fell to $99.1 million from $121.1 million, partly reflecting prior-year in-process R&D costs that did not recur, and G&A expenses declined to $32.6 million from $41.6 million.

On the balance sheet, cash, cash equivalents, and restricted cash totaled $561.5 million as of September 30, 2026. Including roughly $187.2 million in net proceeds from an October 2026 follow-on offering, pro forma cash was approximately $748.7 million, which management said extends the company's cash runway into 2029. Recursion reiterated full-year 2026 cash operating expense guidance of less than $375 million and set 2027 guidance below $360 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical companion for investors tracking names like Recursion Pharmaceuticals. Explore the AI Screener to surface opportunities aligned with your own criteria.

Market Reaction and Investor Sentiment

The earnings beat was a welcome signal for a stock that has been under pressure this year, with shares down modestly in 2026 against broader industry gains. The market's focus, however, appeared to center less on the headline revenue beat—which was heavily dependent on a single milestone payment—and more on the combination of a longer cash runway, disciplined spending, and incremental clinical de-risking. Updated REC-4881 data showing polyp burden reductions in familial adenomatous polyposis (FAP), a hereditary condition that causes numerous precancerous polyps, and the first efficacy signals from REC-1245 gave investors concrete clinical validation rather than platform promises alone. Still, sentiment remains tempered by the early-stage nature of the datasets and by the dilutive follow-on offering that helped fund the extended runway.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should watch several catalysts tied to the pipeline rather than the income statement. Recursion said it anticipates initiating a registrational trial for REC-4881 in the second half of 2027, pending discussions with the U.S. Food and Drug Administration (FDA). The design and timing of that study, given limited regulatory precedent in FAP, will be a key swing factor for the stock.

For REC-1245, an oral degrader targeting a protein called RBM39 (a splicing factor involved in DNA repair), preliminary dose-expansion data in endometrial cancer are expected in the second half of 2027. Because the current efficacy signal rests on a small patient group, investors will watch whether responses hold up as enrollment broadens.

Partnership economics also matter. Sanofi's option of the first development candidate triggered a $10 million milestone and brought total payments under that collaboration to $144 million, with more than $300 million in additional milestones potentially available. Roche's Genentech separately advanced its first validated neuroscience target. Continued milestone flow from these alliances would support the company's funding position without requiring further equity raises.

Finally, spending discipline remains central to the story. With 2027 cash operating expense guidance below $360 million and a runway into 2029, execution on cost controls will determine how much financial flexibility Recursion retains as it advances multiple clinical programs toward later-stage trials.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations